Aaronn Winn News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Re: Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study

Re: Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study
bmj.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bmj.com Daily Mail and Mail on Sunday newspapers.

Aaronn winnAaronp mitchellDear editorNatl cancerCancer prostatic

Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study

Objective To estimate the association between oncologists’ receipt of payments from the pharmaceutical industry and delivery of non-recommended or low value interventions among their patients. Design Cohort study. Setting Fee-for-service Medicare claims. Participants Medicare beneficiaries with a diagnosis of incident cancer (new occurrence of a cancer diagnosis code in proximity to claims for cancer treatment, and no such diagnosis codes during a ≥1 year washout period) during 2014-19, who met additional requirements identifying them as at risk for one of four non-recommended or low value interventions: denosumab for castration sensitive prostate cancer, granulocyte colony stimulating factors (GCSF) for patients at low risk for neutropenic fever, nab-paclitaxel for cancers with no evidence of superiority over paclitaxel, and a branded drug in settings where a generic or biosimilar version was available. Main outcome measures Receipt of the non-recommended or low value drug for

Aaronp mitchellAkriti mishra mezaPeterb bachStacieb dusetzinaAaronn winnMishra mezaFee for service medicareOpen paymentsDurable medical equipment